CL2014002353A1 - Compuesto 2-[[5-cloro-2-[[(6s)-6-[4-(2-hidroxietil)piperazin-1-il]-1-metoxi-6,7,8,9-tetrahidro-5h-benzo[7]anulen-2-il]amino]pirimidin-4-il]amino]-n-metil-benzamida, inhibidor dual de alk y fak; sales del compuesto; composicion farmaceutica; y metodo de tratamiento de gliobalstoma, cancer de prostata y cancer de mama, entre otros. - Google Patents
Compuesto 2-[[5-cloro-2-[[(6s)-6-[4-(2-hidroxietil)piperazin-1-il]-1-metoxi-6,7,8,9-tetrahidro-5h-benzo[7]anulen-2-il]amino]pirimidin-4-il]amino]-n-metil-benzamida, inhibidor dual de alk y fak; sales del compuesto; composicion farmaceutica; y metodo de tratamiento de gliobalstoma, cancer de prostata y cancer de mama, entre otros.Info
- Publication number
- CL2014002353A1 CL2014002353A1 CL2014002353A CL2014002353A CL2014002353A1 CL 2014002353 A1 CL2014002353 A1 CL 2014002353A1 CL 2014002353 A CL2014002353 A CL 2014002353A CL 2014002353 A CL2014002353 A CL 2014002353A CL 2014002353 A1 CL2014002353 A1 CL 2014002353A1
- Authority
- CL
- Chile
- Prior art keywords
- amino
- compound
- anulen
- gliobalstoma
- piperazin
- Prior art date
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 title 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 229940124783 FAK inhibitor Drugs 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 229940125782 compound 2 Drugs 0.000 title 1
- -1 compound salts Chemical class 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 title 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 | |
| PCT/US2013/029304 WO2013134353A1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002353A1 true CL2014002353A1 (es) | 2015-01-09 |
Family
ID=47892060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002353A CL2014002353A1 (es) | 2012-03-06 | 2014-09-05 | Compuesto 2-[[5-cloro-2-[[(6s)-6-[4-(2-hidroxietil)piperazin-1-il]-1-metoxi-6,7,8,9-tetrahidro-5h-benzo[7]anulen-2-il]amino]pirimidin-4-il]amino]-n-metil-benzamida, inhibidor dual de alk y fak; sales del compuesto; composicion farmaceutica; y metodo de tratamiento de gliobalstoma, cancer de prostata y cancer de mama, entre otros. |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9132128B2 (OSRAM) |
| EP (2) | EP3056494B1 (OSRAM) |
| JP (2) | JP6016953B2 (OSRAM) |
| KR (1) | KR102068374B1 (OSRAM) |
| CN (2) | CN104159894B (OSRAM) |
| AU (1) | AU2013229995B2 (OSRAM) |
| CA (1) | CA2865420C (OSRAM) |
| CL (1) | CL2014002353A1 (OSRAM) |
| CY (1) | CY1117565T1 (OSRAM) |
| DK (1) | DK2822939T3 (OSRAM) |
| EA (2) | EA025859B1 (OSRAM) |
| ES (2) | ES2570976T3 (OSRAM) |
| HR (1) | HRP20160387T1 (OSRAM) |
| HU (1) | HUE027976T2 (OSRAM) |
| IL (2) | IL234239A (OSRAM) |
| ME (1) | ME02460B (OSRAM) |
| MX (2) | MX347772B (OSRAM) |
| MY (1) | MY177290A (OSRAM) |
| NZ (1) | NZ630251A (OSRAM) |
| PH (1) | PH12014501979A1 (OSRAM) |
| PL (1) | PL2822939T3 (OSRAM) |
| RS (1) | RS54689B1 (OSRAM) |
| SG (2) | SG10201507865QA (OSRAM) |
| SI (1) | SI2822939T1 (OSRAM) |
| SM (1) | SMT201600134B (OSRAM) |
| UA (1) | UA115052C2 (OSRAM) |
| WO (1) | WO2013134353A1 (OSRAM) |
| ZA (1) | ZA201406147B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115052C2 (uk) * | 2012-03-06 | 2017-09-11 | Сефалон, Інк. | Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2016105529A1 (en) | 2014-12-23 | 2016-06-30 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
| MX2021001398A (es) | 2018-08-07 | 2021-08-16 | In3Bio Ltd | Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico. |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| JP4607879B2 (ja) | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン |
| PL1713806T3 (pl) * | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| AU2005230847B2 (en) | 2004-03-31 | 2012-11-08 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US8962643B2 (en) * | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| JP5512274B2 (ja) * | 2006-10-23 | 2014-06-04 | セファロン、インク． | ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体 |
| RS53588B1 (sr) * | 2006-12-08 | 2015-02-27 | Irm Llc | Jedinjenja i kompozicije kao inhibitori protein kinaza |
| JP4782239B2 (ja) * | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| HUE046402T2 (hu) * | 2009-06-10 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Tetraciklusos vegyületek |
| UA115052C2 (uk) * | 2012-03-06 | 2017-09-11 | Сефалон, Інк. | Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2016105529A1 (en) * | 2014-12-23 | 2016-06-30 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
-
2013
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en not_active Ceased
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 RS RS20160238A patent/RS54689B1/sr unknown
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
-
2014
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
- 2014-09-05 PH PH12014501979A patent/PH12014501979A1/en unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002353A1 (es) | Compuesto 2-[[5-cloro-2-[[(6s)-6-[4-(2-hidroxietil)piperazin-1-il]-1-metoxi-6,7,8,9-tetrahidro-5h-benzo[7]anulen-2-il]amino]pirimidin-4-il]amino]-n-metil-benzamida, inhibidor dual de alk y fak; sales del compuesto; composicion farmaceutica; y metodo de tratamiento de gliobalstoma, cancer de prostata y cancer de mama, entre otros. | |
| UY39630A (es) | Inhibidores de bromodominios | |
| MX383590B (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| BR112013002375A2 (pt) | composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
| CL2014000175A1 (es) | Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| UY35369A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CR20140187A (es) | Compuestos de piperazina alquilados como inhibidores de la actividad btk | |
| EA201391106A1 (ru) | Новые гетероциклические производные | |
| MY177344A (en) | Compounds and their methods of use | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| AR097455A1 (es) | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo | |
| EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
| EA201490888A1 (ru) | Новые производные пурина и их применение для лечения заболевания | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| UA112795C2 (uk) | Біциклічні піразинонові похідні | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
| UA113215C2 (xx) | Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду | |
| NZ709153A (en) | Pyrimidinone derivatives having human neutrophil elastase inhibitory activity | |
| BR112013019160A2 (pt) | novos compostos, composição farmacêutica, uso, processos e métodos |